Metro-Minnesota — Saint Louis Park, Minnesota

Metro-Minnesota is a clinical research site located in Saint Louis Park, Minnesota, United States 55416.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Metro-Minnesota has participated in 1 clinical trials.

Therapeutic areas: Cognition, Aging.

Sponsors: Wake Forest University.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Saint Louis Park

Browse all research sites in Minnesota · View every site in Saint Louis Park

• Methodist Hospital/Park Nicollet Medical Center
• Methodist Hospital
• Park Nicollet Health Services Methodist Hospital
• Heart and Vascular Center at Methodist Hospital
• University of Minnesota Comprehensive Epilepsy Center(MINCEP)
• Park Nicollet Methodist Hospital
• Regions Hospital
• HealthPartners Methodist Hospital
• St. John's Hospital
• Methodist Hospital Inpatient Pharmacy
• University Of Minnesota Medical Center
• CCOP - Metro-Minnesota

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Metro-Minnesota?

Metro-Minnesota has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Metro-Minnesota conducted?

Metro-Minnesota has 1 clinical trials on record. Their work covers Cognition, Aging.

Is Metro-Minnesota accredited by Crixeo Clinical Trials?

Metro-Minnesota has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Metro-Minnesota?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.